TY - JOUR T1 - Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2 JF - medRxiv DO - 10.1101/2021.12.23.21268293 SP - 2021.12.23.21268293 AU - Joseph Newman AU - Nazia Thakur AU - Thomas P. Peacock AU - Dagmara Bialy AU - Ahmed ME Elreafey AU - Carlijn Bogaardt AU - Daniel L. Horton AU - Sammy Ho AU - Thivya Kankeyan AU - Christine Carr AU - Katja Hoschler AU - Wendy S. Barclay AU - Gayatri Amirthalingam AU - Kevin Brown AU - Bryan Charleston AU - Dalan Bailey Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/24/2021.12.23.21268293.abstract N2 - SARS-CoV-2 variants threaten the effectiveness of tools we have developed to mitigate against serious COVID-19. This is especially true in clinically vulnerable sections of society including the elderly. Using sera from BNT162b2 (Pfizer–BioNTech) vaccinated individuals aged between 70 and 89 (vaccinated with two doses 3-weeks apart) we examined the neutralising antibody (nAb) response to wildtype SARS-CoV-2. Between 3 and 20-weeks post 2nd dose, nAb titres dropped 4.9-fold to a median titre of 21.3 (ND80) with 21.6% of individuals having no detectable nAbs at the later time point. Experiments examining the neutralisation of twenty-one different SARS-CoV-2 variant spike proteins confirmed a significant potential for antigenic escape, especially for the Omicron (BA.1), Beta (B.1.351), Delta (B.1.617.2), Theta (P.3), C.1.2 and B.1.638 variants. Interestingly, however, the recently-emerged sub-lineage AY.4.2 was more efficiently neutralised than parental Delta pseudotypes. Combining pseudotype neutralisation with specific receptor binding domain (RBD) ELISAs we confirmed that changes to position 484 in the spike RBD were predominantly responsible for SARS-CoV-2 nAb escape, although the effect of spike mutations is both combinatorial and additive. Lastly, using sera from the same individuals boosted with a 3rd dose of BNT162b2 we showed that high overall levels of neutralising antibody titre can provide significant levels of cross-protection against Omicron. These data provide evidence that SARS-CoV-2 neutralising antibodies wane over time and that antigenically variable SARS-CoV-2 variants are circulating, highlighting the importance of ongoing surveillance and booster programmes. Furthermore, they provide important data to inform risk assessment of new SARS-CoV-2 variants, such as Omicron, as they emerge.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the MRC funded G2P-UK National Virology Consortium; G2P-UK; A National Virology Consortium to address phenotypic consequences of SARS-CoV-2 genomic variation (MR/W005611/1). JN, NT, DB, AE, BC and DB were also funded by The Pirbright Institute BBSRC institute strategic programme grant (BBS/E/I/COV07001, BBS/E/I/00007031, BBS/E/I/00007038, BBS/E/I/00007039 and BBS/E/I/00007034) with NT receiving studentship support from BB/T008784/1. CB and DH were supported by funding from the European Union Horizon 2020 Research and Innovation programme under grant agreement No 773830: One Health European Joint Programme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:United Kingdom Health Security Agency Research Ethics Governance Group of United Kingdom Health Security Agency gave ethical approval for this work; reference NR0253; 18/01/21.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -